Home › Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for...
 

Keywords :   


Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for...

2014-09-16 12:26:38| Chemicals - Topix.net

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development. The study, called ARAMIS, evaluates ODM-201 in men with castration-resistant prostate cancer who have rising Prostate Specific Antigen levels and no detectable metastases.

Tags: iii begin trial phase

Category:Chemicals

Latest from this category

All news
12.11Benjamin Moore Expands Partnership with Roadie to Accelerate Paint Delivery for DIYers and Pros
11.11Clariant Launches Melamine-free Flame Retardant for Intumescent Coatings
11.11Protech Group Acquires Caldwell Chemical Coatings
11.11Asian Paints Reports 2Q 2024-25 Fiscal Results
10.11Clariant Launches Melamine-free Flame Retardant for Intumescent Coatings
09.11Weekly Recap: Nippon Paint, AkzoNobel, PPG Top This Weeks Stories
08.11Statement from the U.S. Green Building Council on the 2024 Election Results
08.11Axalta Celebrates the Opening of its Global Headquarters in the Philadelphia Navy Yard
Chemicals »
16.11GLAY REVIEW
16.111China Princess
16.11 CB716 5P
16.11TXT freeze
16.11/
16.11
16.11TOMICA D D limited stage
16.11
More »